Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Decitabine (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 22 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 09 Jul 2013 Planned primary completion date changed from 1 Jun 2013 to 1 Oct 2022 as reported by ClinicalTrials.gov record.